Quiz (low difficulty): Why didn’t ENTA establish the “value share” of ABT-450 within ABBV’s 3-DAA regimen a long time ago instead of having to negotiate this with ABBV at the last minute? Waited to see GILD pricing of Sovaldi? I guess it appears the market is disappointed with the 30% share value of the 3-DAA as well.